NCT02050919View on ClinicalTrials.gov

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 3, 2013

Primary Completion Date

May 7, 2018

Study Completion Date

December 31, 2020

Conditions
Pleomorphic RhabdomyosarcomaStage IIB Adult Soft Tissue Sarcoma AJCC v7Stage III Adult Soft Tissue Sarcoma AJCC v7Stage IV Adult Soft Tissue Sarcoma AJCC v7
Interventions
DRUG

Epirubicin Hydrochloride

Given IV

RADIATION

External Beam Radiation Therapy

Undergo EBRT

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Sorafenib Tosylate

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER